$14.800
-0.759 (-5.13%)收盘时
PAYS 资讯
PAYS 事件
Sees Q3 Revenue of $28.5M-$30M
Sees Q3 revenue $28.5M-$30M, consensus $26.98M.
Paysign Reports Q2 Revenue of $28.25M
Reports Q2 revenue $28.25M, consensus $26.36M. "Paysign delivered a strong second quarter, achieving record revenue, net income, and adjusted EBITDA while continuing to expand margins," said Mark Newcomer, President and CEO of Paysign. "Strong growth in our patient affordability business, steady performance in plasma donor compensation, and disciplined execution across the company drove meaningful operating leverage and profitability, reinforcing the multiyear strategy we have been building. With momentum across the business and a robust pipeline of opportunities, we intend to remain focused on sustainable growth, continued margin expansion, and creating long-term value for shareholders."
Raises FY26 Revenue Outlook to $114M-$117M
Raises FY26 revenue view to $114M-$117M from $106.5M-$110.5M, consensus $108.55M.
Sees Q2 Revenue of $26.2M-$26.7M
Sees Q2 revenue $26.2M-$26.7M. Sees Q2 adjusted EBITDA $7.7M-$8.5M.
Paysign Sees 2026 Revenue Guidance of $106.5M-$110.5M
Sees revenue $106.5M-$110.5M. Sees adjusted EBITDA $30M-$33M. "Our first quarter results exceeded guidance across every line of the income statement," commented Jeff Baker, Chief Financial Officer of Paysign. "Revenue, operating margin and net income all finished above the high end of our prior ranges, driven by fixed cost leverage and a continued mix shift toward patient affordability. We are reiterating our full-year 2026 ranges, and the momentum from the first quarter supports our confidence in achieving the upper half of our guidance ranges...The second quarter reflects the seasonal pattern we have laid out previously: pharma revenue is highest in the first quarter as patient affordability claims peak, and plasma builds through the balance of the year. For the full year, we continue to expect plasma and pharma to contribute roughly equally to revenue, with margins expanding across the income statement and net income nearly doubling over 2025 as patient affordability scales. With a strong unrestricted cash position, no bank debt and a growing cash flow profile, we are well positioned to fund our 2026 investment plans and execute against the financial framework we have communicated."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。